Archive for July, 2010

Geron Gets FDA OK to Test Embryonic Stem Cell Therapy on Spinal Cord Injuries

The Food and Drug Administration cleared the way on Friday for California biotech firm Geron ( GERN ) to begin human clinical trials of its experimental embryonic stem cell-based therapy to heal spinal cord injuries in …

Geron Gets Cleared for First Embryonic Stem-Cell Test

Geron Corp. said it was cleared by U.S. regulators to proceed with the first human test of an embryonic stem-cell therapy, aimed at patients with spinal-cord injuries. The shares rose 17 percent.

Geron says FDA lifts hold on stem cell trial

Regulators are giving the all-clear to a clinical trial that will test embryonic stem cells as a treatment for spinal cord injury, says the developer of the treatment, Geron Corp. Geron says the Food and Drug Administration removed a clinical hold on its… Spinal cord injury – Food and Drug Administration – Clinical trial – Geron Corporation – Embryonic stem cell

Geron Cleared to Test Embryonic Stem-Cell Therapy

Geron Corp. said U.S. regulators cleared the company to proceed with the first medical trial of embryonic stem-cell treatment in patients with spinal-cord injuries. The shares rose as much as 16 percent.

Geron Cleared by FDA to Test Embryonic Stem-Cell Treatment; Shares Climb

Geron Corp. said U.S. regulators cleared the company to proceed with the first medical trial of an embryonic stem-cell treatment, aiming at patients who have spinal-cord injuries. The shares rose as much as 16 percent.

Effective inducing systems of hepatic differentiation from bone marrow mesenchymal stem cells

Recent studies suggest that MSCs possess a greater differentiation potential than once thought and several hepatic differentiation protocols from bone marrow cells have been established. However, the incidence of bone marrow-derived hepatocytes was low. Moreover, a long culture period is needed in most cases.

Liberty Analytics Co. Initiates Independent Research Coverage on International Stem Cell Corp.

About LAC: Liberty Analytics Co. is a leading provider of independent investment research in North America. Our services include research analysis on the large, small- and micro-cap markets, real-time news and financial …

Geron Rallies As FDA Green Lights Stem Cell Study

Geron Rallies As FDA Green Lights Stem Cell Study

Geron To Proceed With First Human Clinical Trial Of Embryonic Stem Cell-Based Therapy

Geron Corporation (Nasdaq:GERN) announced today that the U.S. Food and Drug Administration (FDA) has notified the company that the clinical hold placed on Geron’s Investigational New Drug (IND) application …

Healthy Living: Stem cell research

Researchers at Mt. Sinai made an important finding in the field of stem cell research that can have an impact on how doctors treat heart disease. Health reporter Kafi Drexel filed the following report.